Healthcare Industry News: Mobetron
News Release - March 21, 2007
IntraOp Medical Delivers Third Mobetron, Advanced Intraoperative Electron Radiation Therapy System, to Japan19th Mobetron Unit Delivered Worldwide
SUNNYVALE, Calif.--(HSMN NewsFeed)--IntraOp Medical Corporation (OTCBB: IOPM ), a provider of innovative technology solutions for the treatment and eradication of cancer, today announced it has delivered Mobetron® to the Gunma Prefectural Cancer Center in Japan. Mobetron is a proprietary, mobile, self-shielded device designed to deliver intraoperative electron-beam radiation therapy (IOERT) to cancer patients during their tumor removal surgery. With this delivery, IntraOp has delivered 19 Mobetron units worldwide, including three in Japan.
Gunma Prefectural Cancer Center is one of 80 hospitals in Japan with active IOERT programs. Although Japan is considered the birthplace of modern IOERT, the Center, like almost all Japanese centers, presently transports the patient, in the midst of surgery, from the operating room to the radiation department to receive the IOERT treatment. Mobetron, by contrast, is self-shielded and delivers IOERT in the operating room, without patient transportation. The Gunma unit and Mobetron delivered to Nagoya University Hospital in September 2006 are the first two IOERT systems in the country to be located in a standard operating room.
"We have been working diligently with our partner in Japan, Chiyoda Technol Corporation, to introduce Mobetron's modern IOERT technology to Japan, and we are gratified that these efforts are beginning to bear fruit," said Dr. Donald A. Goer, President and Chief Executive Officer of IntraOp. "Mobetron allows treatment to be delivered more cost effectively and conveniently than the Center's current IOERT method, making IOERT treatment more routinely available to a greater proportion of the Center's patients. We believe other hospitals in Japan are likely to follow the example of Gunma and Nagoya."
With Mobetron, radiation and surgical oncologists can pinpoint the exact area that requires radiation and immediately deliver high doses directly to the affected tissue during cancer surgery. Hospitals can wheel Mobetron between existing operating rooms without the costly renovations required to accommodate traditional radiation therapy devices. Key patient benefits of this early and powerful start to radiation therapy include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects.
About Gunma Prefectural Cancer Center
With a population of about two million people, Gunma, located northwest of Tokyo, is the 19th most populous of Japan's 47 prefectures. Gunma Prefectural Cancer Center is the main cancer treatment center for the prefecture. The hospital's staff, which includes Chief of Surgery, Dr. Toshio Sawada, its Chief of Radiation Therapy, Dr. Yoshio Tamaki, and its Chief of Operations, Dr. Nobuhiro Saruki, intends to focus initially on the use of IOERT for pancreatic cancer and early-stage breast cancer.
IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer radiation therapy safely and effectively - for all cancer patients. The company's flagship product, Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use Mobetron as a vital part of their comprehensive cancer program.
For more information on IntraOp Medical Corporation, please visit www.intraopmedical.com
This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.
Source: IntraOp Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.